Infection of DBA/2 or C3H/HeJ mice by intraperitoneal injection of vaccinia virus elicits activated macrophages, cytolytic and cytostatic for S91-melanoma tumor cells.

R J Natuk, J A Byrne, J A Holowczak
Author Information

Abstract

Murine peritoneal macrophages harvested 3-4 days after IP injection of vaccinia virus lysed S91-melanoma tumor cells in vitro; enhanced tumoricidal activity was measured with effector macrophages prepared 5-6 days after vaccinia virus infection. Treatment of virus-elicited macrophages prepared from DBA/2 mice with anti-asialo-GM1 antiserum, anti-Thy 1.2 antiserum or anti-Iad antiserum in the presence of complement so that cells sensitized with antibodies were lysed, did not reduce the measured level of tumoricidal activity indicating that macrophages [Ia(-); asialo GM1(-)] and not natural killer cells [asialo GM1(+); Thy 1.2(+/-)] or T-cells [Thy 1.2(+)] were responsible for mediating the lysis of S91-melanoma tumor cells. When incubated with virus-elicited macrophages but not thioglycollate-elicited macrophages, the ability of S91-melanoma tumor cells. to synthesize DNA was completely blocked. The results of these experiments support the view that one aspect of antitumor immunity enhanced during immunotherapy with vaccinia virus is the activation of macrophages which have cytolytic as well as cytostatic effects on melanoma tumor cells.

References

  1. J Immunol. 1979 Feb;122(2):475-81 [PMID: 84023]
  2. Biochim Biophys Acta. 1962 Aug 20;61:290-301 [PMID: 14452174]
  3. J Immunol. 1979 Aug;123(2):568-71 [PMID: 458147]
  4. Transplant Proc. 1970 Mar;2(1):92-103 [PMID: 4107297]
  5. Aust N Z J Surg. 1984 Aug;54(4):303-15 [PMID: 6207805]
  6. Cell Immunol. 1985 Oct 1;95(1):95-104 [PMID: 3875426]
  7. Science. 1966 Dec 2;154(3753):1186-9 [PMID: 4288399]
  8. Arch Dermatol. 1974 May;109(5):668-73 [PMID: 4828533]
  9. Cancer Immunol Immunother. 1983;16(2):81-7 [PMID: 6607104]
  10. Cancer. 1964 Jun;17:708-12 [PMID: 14172076]
  11. Biken J. 1981 Dec;24(4):153-8 [PMID: 7346041]
  12. J Leukoc Biol. 1985 May;37(5):597-614 [PMID: 3884721]
  13. J Immunol. 1985 Jan;134(1):108-13 [PMID: 3155458]
  14. J Exp Med. 1980 Sep 1;152(3):657-73 [PMID: 6997425]
  15. Br J Cancer. 1974 Nov;30(5):401-15 [PMID: 4469193]
  16. Virology. 1985 Aug;145(1):1-23 [PMID: 3874471]
  17. J Exp Med. 1980 Dec 1;152(6):1734-44 [PMID: 6450260]
  18. Int J Cancer. 1982 May 15;29(5):567-74 [PMID: 7095901]
  19. J Immunol. 1981 Jan;126(1):263-9 [PMID: 6450236]
  20. J Leukoc Biol. 1985 May;37(5):629-39 [PMID: 3156939]
  21. Scand J Immunol. 1982 Nov;16(5):421-30 [PMID: 6983715]
  22. Surgery. 1984 Oct;96(4):791-800 [PMID: 6091287]
  23. Cell. 1979 Mar;16(3):649-59 [PMID: 287567]
  24. Science. 1982 Oct 15;218(4569):295-6 [PMID: 6812218]
  25. J Biol Response Mod. 1983;2(6):586-96 [PMID: 6663322]
  26. Yale J Biol Med. 1975 Nov;48(5):423-9 [PMID: 1108459]
  27. Annu Rev Immunol. 1984;2:283-318 [PMID: 6100475]
  28. Cell Immunol. 1977 Feb;28(2):404-15 [PMID: 191199]
  29. Microbiol Immunol. 1982;26(9):831-42 [PMID: 7154991]
  30. Exp Cell Biol. 1983;51(3):158-64 [PMID: 6852344]
  31. Transplant Rev. 1974;19(0):89-120 [PMID: 4601807]
  32. Eur J Immunol. 1984 Sep;14(9):839-43 [PMID: 6236991]
  33. Aust J Dermatol. 1961 Dec;6:113-8 [PMID: 13866770]
  34. Blood. 1961 May;17:643-9 [PMID: 13718493]
  35. J Immunol. 1973 Mar;110(3):801-10 [PMID: 4688920]
  36. Cancer Immunol Immunother. 1990;31(5):305-11 [PMID: 2376048]
  37. Biochem J. 1963 Oct;89:150-6 [PMID: 14097356]
  38. J Immunol. 1983 Aug;131(2):826-32 [PMID: 6408190]
  39. N Engl J Med. 1980 Nov 13;303(20):1174-5 [PMID: 6999351]
  40. Proc Natl Acad Sci U S A. 1983 Apr;80(7):2031-5 [PMID: 6572960]
  41. Annu Rev Immunol. 1984;2:395-428 [PMID: 6242349]
  42. Dermatologica. 1973;146(3):156-62 [PMID: 4717482]
  43. Br J Cancer. 1978 Jun;37(6):1078-82 [PMID: 678429]
  44. Eur J Immunol. 1980 Mar;10(3):175-80 [PMID: 6966574]
  45. Aust J Exp Biol Med Sci. 1973 Jun;51(3):393-8 [PMID: 4358302]
  46. J Natl Cancer Inst. 1975 May;54(5):1177-84 [PMID: 1092874]
  47. Cancer Immunol Immunother. 1983;16(2):67-71 [PMID: 6362848]
  48. J Immunol. 1982 Dec;129(6):2802-7 [PMID: 6982943]
  49. J Immunol. 1978 Sep;121(3):813-6 [PMID: 357655]
  50. Eur J Immunol. 1975 Feb;5(2):112-7 [PMID: 1234049]
  51. J Immunol Methods. 1977;14(3-4):267-9 [PMID: 65435]
  52. Biken J. 1984 Mar;27(1):1-7 [PMID: 6385960]

Grants

  1. CA-09069/NCI NIH HHS

MeSH Term

Animals
Cytotoxicity, Immunologic
DNA, Neoplasm
Immunotherapy
Injections, Intraperitoneal
Killer Cells, Natural
Macrophage Activation
Macrophages
Melanoma
Mice
Mice, Inbred C3H
Mice, Inbred DBA
Thioglycolates
Thymidine
Vaccinia virus

Chemicals

DNA, Neoplasm
Thioglycolates
Thymidine

Word Cloud

Created with Highcharts 10.0.0macrophagescellstumorvacciniavirusS91-melanomaantiserum12]daysinjectionlysedenhancedtumoricidalactivitymeasuredpreparedvirus-elicitedDBA/2mice-GM1+cytolyticcytostaticMurineperitonealharvested3-4IPvitroeffector5-6infectionTreatmentanti-asialo-GM1anti-Thyanti-Iadpresencecomplementsensitizedantibodiesreducelevelindicating[Iaasialonaturalkiller[asialoThy+/-T-cells[Thyresponsiblemediatinglysisincubatedthioglycollate-elicitedabilitysynthesizeDNAcompletelyblockedresultsexperimentssupportviewoneaspectantitumorimmunityimmunotherapyactivationwelleffectsmelanomaInfectionC3H/HeJintraperitonealelicitsactivated

Similar Articles

Cited By (2)